InsidersTradesSigma
ACCURAY INC Stock: price and insider trades · United States · SEC (Form 4)
Track the ACCURAY INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, ACCURAY INC has published 180 public disclosures. Market capitalisation: €30.9m. The latest transaction was disclosed on 3 March 2026 (Levée d'options). Among the most active insiders: Winter Suzanne C. The full history is openly available.
180
Insider Decl.
0
Thresholds
€456,126
13 ops.
Buy Volume
€2m
57 ops.
Sell Volume
23Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 22,683 of 25,899 companies
24.4
score / 100
Value29
Quality20
FCF yld-18%
Earn yld-5.1%
EV/EBITDA10.2x
ROE-101%
Gross mgn32%
Net mgn-0.3%
Debt/EBITDA8.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 3 March 2026
Declarations180 total
83,723 shares0Common StockSEC:0001214659-26-002732:0
28,969 shares@ US$0.55100.0% of flowCommon StockSEC:0001214659-26-002732:1
895,391 shares0Common StockSEC:0001214659-25-017519:0
50,000 shares0Common StockSEC:0001214659-25-017520:0
50,314 shares0Common StockSEC:0001214659-25-017523:0
64,477 shares@ US$1.0219.3% of flowCommon StockSEC:0001214659-25-017523:1
44,025 shares0Common StockSEC:0001214659-25-017524:0
57,341 shares@ US$1.0222.3% of flowCommon StockSEC:0001214659-25-017524:1
56,603 shares0Common StockSEC:0001214659-25-017241:0
56,603 shares0Common StockSEC:0001214659-25-017242:0
22,642 shares@ US$1.053.8% of flowCommon StockSEC:0001214659-25-017242:1
56,603 shares0Common StockSEC:0001214659-25-017243:0
45,620 shares0Common StockSEC:0001214659-25-017244:0
56,603 shares0Common StockSEC:0001214659-25-017245:0
56,603 shares0Common StockSEC:0001214659-25-017246:0
22,642 shares@ US$1.053.2% of flowCommon StockSEC:0001214659-25-017246:1
56,603 shares0Common StockSEC:0001214659-25-017247:0
3,552 shares@ US$1.552.1% of flowCommon StockSEC:0001214659-25-008761:0
35,123 shares@ US$1.5516.3% of flowCommon StockSEC:0001214659-25-008762:0
2,013 shares@ US$1.981.7% of flowCommon StockSEC:0001214659-25-000073:0
29,749 shares@ US$2.1520.7% of flowCommon StockSEC:0001214659-24-019893:0
42,265 shares@ US$2.1528.8% of flowCommon StockSEC:0001214659-24-019895:0
24,675 shares@ US$2.1519.6% of flowCommon StockSEC:0001214659-24-019903:0
26,687 shares@ US$2.1524.1% of flowCommon StockSEC:0001214659-24-019894:0
119,698 shares@ US$2.1525.2% of flowCommon StockSEC:0001214659-24-019892:0
25 of 180 declarations
About ACCURAY INC
Accuray Incorporated (ticker: ARAY) is a U.S.-based medical technology company listed on NASDAQ in the United States, focused on precision radiation therapy systems for cancer treatment and neurosurgical radiosurgery. Headquartered in Madison, Wisconsin, Accuray positions itself as a differentiated provider of advanced radiation oncology solutions for hospitals and treatment centers seeking highly targeted delivery for complex cases while also making standard workflows easier to manage. For equity investors, that places the company squarely in the healthcare equipment sub-sector, with exposure to clinical adoption cycles, capital purchasing decisions by providers, and the regulatory environment that governs medical devices. ([accuray.com](https://www.accuray.com/company/)) Founded in 1990, Accuray built its business around two flagship platforms, CyberKnife and TomoTherapy, and has since expanded its portfolio with Radixact, Accuray Precision treatment planning software, and iDMS data management tools. The company designs, manufactures, sells, and services radiation therapy systems and related software, creating a business model that combines higher-value system placements with recurring service revenue tied to the installed base. That mix is strategically important because it can help balance the lumpiness of system orders with more stable service economics over time. ([accuray.com](https://www.accuray.com/company/)) Competitive positioning is centered on precision, automation, and clinical versatility. Accuray markets its technology for oncology and neuro-radiosurgery applications and emphasizes its ability to treat difficult-to-address tumors with accuracy. The company’s global footprint is also a defining feature: manufacturing facilities are located in Madison, Wisconsin and Chengdu, China, with regional offices in Switzerland, Japan, China, and Hong Kong. This international presence supports commercialization, but it also introduces meaningful exposure to supply chain disruption, tariffs, foreign exchange volatility, and other cross-border operating risks. ([accuray.com](https://www.accuray.com/company/)) Recent developments matter for the investment case. In August 2025, Accuray reported fiscal fourth-quarter and full-year 2025 results, highlighted service revenue growth, completed debt refinancing, and issued fiscal 2026 guidance. Management guided to total net revenue of $471 million to $485 million and adjusted EBITDA of $31 million to $35 million. The company also pointed to continued progress in customer adoption, product portfolio expansion, and its China joint venture. For investors tracking SEC Form 4 insider activity, the name sits in a small-cap healthcare technology profile where operational execution, balance-sheet management, and international commercialization are all key swing factors. ([investors.accuray.com](https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fourth-quarter-and-fiscal-2025-financial-results))
